Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltz in Pyoderma Gangrenosum
NCT03137160Phase 2Completed
- Sponsor
- The Ohio State University
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixekizumab in pyoderma gangrenosum (PG), sponsored by The Ohio State University. Primary endpoint: Investigator Global Assessment at 12 weeks. Started May 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT03137160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137160.